

DIASORIN CE MARKS THEIR ARIES® FLU A/B & RSV+SARS-CoV-2 LOWPLEX ASSAY

THE ARIES® FLU A/B & RSV+SARS-COV-2 ASSAY IS:

- A MOLECULAR PANEL TEST TO DIFFERENTIATE SARS-COV-2, RSV, FLU A AND FLU B VIRUSES
- DESIGNED FOR USE ON THE SAMPLE-TO-ANSWER ARIES® SYSTEMS FROM NASOPHARYNGEAL
- AVAILABLE IN COUNTRIES ACCEPTING CE MARK

Saluggia, Italy, May 20, 2022 - DiaSorin (FTSE MIB: DIA) today announced it CE marked its ARIES® Flu A/B & RSV+SARS-CoV-2 Assay, a molecular panel test designed to detect the four most common respiratory viruses and their underlying respiratory infections. The test is designed for use on the sample-to-answer ARIES® System that offers clinical laboratories a fully automated diagnostic workflow, thereby generating actionable results with efficiency and minimal hands-on time.


Respiratory infections may be caused by a variety of pathogens, but their overlapping symptoms challenge physicians to effectively diagnose the cause of infection, as well as to determine the effective course of patient management.

Furthermore, patients can experience co-infections with more than one respiratory virus. Therefore, as compared to single pathogen tests, multi-target pathogen testing is a more effective method for identifying co-infection cases, in addition to guiding appropriate treatment.

The ARIES® Flu A/B & RSV+SARS-CoV-2 Assay offers a highly sensitive and specific multiplexing approach for the most common respiratory viruses: influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2—the virus that causes COVID-19. Results are then generated in a single workflow from the same patient sample, which thus enables rapid detection for the differential diagnosis of a single pathogen or potential cases of co-infection. The ARIES® Flu A/B & RSV+SARS-CoV-2 Assay workflow allows up to 12 nasopharyngeal swab samples in one run, and it produces results in approximately two hours. Furthermore, the ARIES® System enables the flexibility for labs to address their respiratory testing needs during high COVID-19 pandemic or flu seasonal demands.

"The ARIES® Flu A/B & RSV+SARS-CoV-2 test further enriches the existing offer available on our lowplex molecular platforms, demonstrating our continuous commitment to provide innovative diagnostic solutions in the field of respiratory diseases on this technology," said Angelo Rago, president of Luminex. "This new test will allow hospitals and clinical labs to adopt a scalable diagnostic approach and expand their testing to all four targets that are important for pediatric and adult patients."





For additional information, please contact:

Riccardo Fava

DiaSorin

Corporate Vice President Communication & Investor Relations Tel: +39.0161.487988 riccardo.fava@diasorin.it

Emanuela Salvini Investor Relator Tel: +39.0161.487567 emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com